

# Surein Arulananda

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5094145/publications.pdf>

Version: 2024-02-01

24  
papers

489  
citations

1163117

8  
h-index

713466

21  
g-index

24  
all docs

24  
docs citations

24  
times ranked

989  
citing authors

#	ARTICLE	IF	CITATIONS
1	The role of BCL-2 family proteins and therapeutic potential of BH3-mimetics in malignant pleural mesothelioma. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 413-424.	2.4	9
2	A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma. <i>Cell Death Discovery</i> , 2021, 7, 122.	4.7	23
3	Occult Gastrointestinal Perforation in a Patient With EGFR-Mutant Non-Small-Cell Lung Cancer Receiving Combination Chemotherapy With Atezolizumab and Bevacizumab: Brief Report. <i>Clinical Lung Cancer</i> , 2020, 21, e57-e60.	2.6	5
4	Gefitinib and Pemetrexed Improve Survival in EGFR-Mutated NSCLC – Tarring all Patients With the Same Brush?. <i>Journal of Thoracic Oncology</i> , 2020, 15, 12-14.	1.1	0
5	Adjuvant TKI therapy in resected EGFR-mutant non-small-cell lung cancer – ready for prime time?. <i>Translational Lung Cancer Research</i> , 2020, 9, 1728-1731.	2.8	0
6	BCL-XL is an actionable target for treatment of malignant pleural mesothelioma. <i>Cell Death Discovery</i> , 2020, 6, 114.	4.7	13
7	&lt;p&gt;A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia&lt;/p&gt;. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 1177-1189.	4.3	21
8	Management of non-small cell lung cancer with resistance to epidermal growth factor receptor tyrosine kinase inhibitor: case discussion. <i>Journal of Thoracic Disease</i> , 2020, 12, 159-164.	1.4	7
9	Nivolumab resulting in persistently elevated troponin levels despite clinical remission of myocarditis and myositis in a patient with malignant pleural mesothelioma: case report. <i>Translational Lung Cancer Research</i> , 2020, 9, 360-365.	2.8	13
10	A pilot study of intrahepatic yttrium-90 microsphere radioembolization in combination with intravenous cisplatin for uveal melanoma liver – only metastases. <i>Cancer Reports</i> , 2019, 2, e1183.	1.4	7
11	DDR Alterations as a Surrogate Marker for TMB in SCLC – Use it or Lose it?. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1498-1500.	1.1	3
12	Standard dose osimertinib for erlotinib refractory T790M-negative EGFR-mutant non-small cell lung cancer with leptomeningeal disease. <i>Journal of Thoracic Disease</i> , 2019, 11, 1756-1764.	1.4	8
13	BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival. <i>Cell Death and Disease</i> , 2019, 10, 342.	6.3	125
14	RET – rearranged non-small cell lung cancer and therapeutic implications. <i>Internal Medicine Journal</i> , 2019, 49, 1541-1545.	0.8	6
15	In Reply to Leone. <i>Journal of Thoracic Oncology</i> , 2018, 13, e22-e23.	1.1	0
16	Elderly patients with stage III NSCLC survive longer when chemotherapy is added to radiotherapy – fortune favours the bold. <i>Translational Lung Cancer Research</i> , 2018, 7, S388-S392.	2.8	4
17	Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. <i>European Journal of Cancer</i> , 2018, 105, 88-102.	2.8	53
18	Mismatch Repair Protein Defects and Microsatellite Instability in Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1588-1594.	1.1	35

#	ARTICLE	IF	CITATIONS
19	BRAF Mutationsâ€”A Good News Story for Immune Checkpoint Inhibitors in Oncogene-Addicted NSCLC?. Journal of Thoracic Oncology, 2018, 13, 1055-1057.	1.1	3
20	Clinical correlates of severe thrombocytopenia from temozolomide in glioblastoma patients. Internal Medicine Journal, 2018, 48, 1206-1214.	0.8	7
21	Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Nonâ€”Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 1728-1732.	1.1	143
22	The ADAM Trial. JAMA Oncology, 2017, 3, 66.	7.1	1
23	Pulmonary metastases: A rare manifestation of the most common cancer. Australasian Journal of Dermatology, 2013, 54, e70-e73.	0.7	1
24	Bronchoepidural Fistula in a Man with Actinomyces Complicated Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 1761-1762.	1.1	2